
From: Tom P Napoli <Tom.Napoli@actavis.com>
Sent: Tuesday, January 14, 2014 6:32 AM
To: Clarke, Michael R.
Subject: RE: Anti-Diversion Industry Working Group February Meeting

Actually, I may have spoken too soon. My Boss has scheduled a 2 day meeting on 2.18-19

From: Michael R. Clarke
Sent: Tuesday, January 14, 2014 6:03 AM
To: Tom P Napoli
Subject: FW: Anti-Diversion Industry Working Group February Meeting

Tom,

I have a conflict and can't attend the February 18 meeting in Chicago. Can you go?

Michael

Michael Russell Clarke
VP, Ethics & Compliance - Americas
Actavis, Inc.
michael.r.clarke@actavis.com

862.261.7850
908.514.2256 - mobile

From: Lohman, Donald A [<mailto:Donald.Lohman@mallinckrodt.com>]
Sent: Monday, January 13, 2014 4:49 PM
To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com> (Robert.Giacalone@cardinalhealth.com); Cameron, Todd (Todd.Cameron@cardinalhealth.com); Napoli, Thomas; Clarke, Michael R.; THernandez@QualitestRX.com; MRichardson@qualitestrx.com; Mays, Steve (SMays@amerisourcebergen.com); EHazewski@amerisourcebergen.com; Campbell, Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald (Donald.Walker@McKesson.com); krista.peck@mckesson.com; william.stivers@hdsmith.com
Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V; Phillips, Lynn; Wuestner, Joe A
Subject: RE: Anti-Diversion Industry Working Group February Meeting

All –

Given our current focus on the pharmacist video and the direct involvement of the NABP in that process, we thought it best to have our next meeting in Chicago to facilitate NABP's attendance. Of the dates under consideration, NABP is available on February 18th, so we will have our next meeting on that date. The location will be the Chicago offices of Ropes & Gray at 32nd Floor, 191 North Wacker Drive, Chicago, IL 60606. Directions are can be found here: <http://www.ropesgray.com/locations/chicago.aspx>. I will have more details in the next week or so. Please mark your calendars for 2/18.

In the meantime, the RFP has gone out and that process is underway.

Thanks.

1

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER



ALLERGAN_MDL_02187686

P-02402_00001

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance
Mallinckrodt Pharmaceuticals

675 McDonnell Blvd. | Hazelwood, MO 63042 | USA
T: 314.654.3927 | M: 314.308.4961

donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

From: Lohman, Donald A
Sent: Thursday, January 02, 2014 10:00 AM
To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com> (Robert.Giacalone@cardinalhealth.com); Cameron, Todd (Todd.Cameron@cardinalhealth.com); 'Tom P Napoli'; mclarke@actavis.com; THernandez@QualitestRX.com; MRichardson@qualitestr.com; Mays, Steve (SMays@amerisourcebergen.com); 'EHazewski@amerisourcebergen.com'; Campbell, Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald (Donald.Walker@McKesson.com); krista.peck@mckesson.com; william.stivers@hdsmith.com
Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V; Phillips, Lynn; Wuestner, Joe A
Subject: Anti-Diversion Industry Working Group Meeting Follow Up: CALL

All –

I would like to set up a brief call on Monday, 1/6/14, from 2:00-2:30 pm EST to discuss the following:

- Pharmacist video:
 - Update from Bob on the latest NABP/DEA meeting where NABP expressed that they see real value in this video given the work being done on their red flag collaboration project.
 - We received some preliminary feedback that the video will cost approximately \$35K per company (around \$250,000 total). I wanted to touch base on this before the RFP was amended to reflect this change and issued.
 - Confirm that there are no additional comments to the RFP.
 - Get any other recommendations for production companies.

- Next Meeting
 - Location?
 - Date in February.

I will send out a separate calendar invitation.

Happy New Year.

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance
Mallinckrodt Pharmaceuticals
675 McDonnell Blvd. | Hazelwood, MO 63042 | USA

2

T: 314.654.3927 | M: 314.308.4961

donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

From: Lohman, Donald A

Sent: Tuesday, December 17, 2013 9:48 AM

To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com> (Robert.Giacalone@cardinalhealth.com); Cameron, Todd (Todd.Cameron@cardinalhealth.com); 'Tom P Napoli'; mclarke@actavis.com; THernandez@QualitestRX.com; MRichardson@qualitestrx.com; Mays, Steve (SMays@amerisourcebergen.com); 'EHazewski@amerisourcebergen.com'; Campbell, Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald (Donald.Walker@McKesson.com); krista.peck@mckesson.com; william.stivers@hdsmith.com

Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V; Phillips, Lynn; Wuestner, Joe A

Subject: RE: Anti-Diversion Industry Working Group Meeting Follow Up

All –

Attached for your review and comment is a draft RFP for the pharmacist video. **Please provide any comments and the names of any production companies by Friday as we would like to send out next week.** Please copy Lynn Phillips on any response. Also attached is Linden and Larry's magnum opus referred to in the RFP.

Please let me know what dates you are available in February for our next meeting. As of now, all dates are good **except for February 5-7 and February 12-14.**

Thanks.

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance
Mallinckrodt Pharmaceuticals

675 McDonnell Blvd. | Hazelwood, MO 63042 | USA

T: 314.654.3927 | M: 314.308.4961

donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

From: Lohman, Donald A

Sent: Tuesday, December 03, 2013 9:04 AM

To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com> (Robert.Giacalone@cardinalhealth.com); Cameron, Todd (Todd.Cameron@cardinalhealth.com); 'Tom P Napoli'; mclarke@actavis.com; THernandez@QualitestRX.com; MRichardson@qualitestrx.com; Mays, Steve (SMays@amerisourcebergen.com); 'EHazewski@amerisourcebergen.com'; Campbell,

Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald (Donald.Walker@McKesson.com); krista.peck@mckesson.com; william.stivers@hdsmith.com
Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V; Phillips, Lynn
Subject: RE: Anti-Diversion Industry Working Group Meeting

All –

Attached is the agenda for our meeting on December 10th.

For those of you arriving Monday evening, we will be getting together for dinner. I will have details later this week.

Please contact me if you have any questions or concerns. See you next week.

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance
Mallinckrodt Pharmaceuticals
675 McDonnell Blvd. | Hazelwood, MO 63042 | USA
T: 314.654.3927 | M: 314.308.4961
donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

From: Lohman, Donald A
Sent: Monday, November 25, 2013 11:21 AM
To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com> (Robert.Giacalone@cardinalhealth.com); Cameron, Todd (Todd.Cameron@cardinalhealth.com); 'Tom P Napoli'; mclarke@actavis.com; THernandez@QualitestRX.com; MRichardson@qualitestrx.com; Mays, Steve (SMays@amerisourcebergen.com); 'EHazewski@amerisourcebergen.com'; Campbell, Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald (Donald.Walker@McKesson.com); krista.peck@mckesson.com; william.stivers@hdsmith.com
Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V; Phillips, Lynn
Subject: RE: Anti-Diversion Industry Working Group Meeting

All –

The details of our December 10th meeting have been confirmed. The location is the offices of Arent Fox at 1717 K Street, NW, Washington, DC 20036. We will meet from 8 am to 5 pm. Please make your travel arrangements. I am checking on dinner the night before.

Our guests:

Regina LaBelle, Chief of Staff from ONDCP
Lisa Robin, Chief Advocacy Officer from the Federation of State Medical Boards

Sherry Green, CEO of the National Alliance for Model State Drug Laws

I am planning on getting an agenda out before Thanksgiving. Please contact me with any questions.

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance

Mallinckrodt Pharmaceuticals

675 McDonnell Blvd. | Hazelwood, MO 63042 | USA

T: 314.654.3927 | M: 314.308.4961

donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

From: Lohman, Donald A

Sent: Friday, November 15, 2013 4:11 PM

To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com>

(Robert.Giacalone@cardinalhealth.com); Cameron, Todd

(Todd.Cameron@cardinalhealth.com); 'Tom P Napoli'; mclarke@actavis.com;

THernandez@QualitestRX.com; MRichardson@qualitestrx.com; Mays, Steve

(SMays@amerisourcebergen.com); 'EHazewski@amerisourcebergen.com'; Campbell,

Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald

(Donald.Walker@McKesson.com); krista.peck@mckesson.com;

william.stivers@hdsmith.com

Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V;

Phillips, Lynn

Subject: RE: Anti-Diversion IWG

All –

Quick update on the December 10th meeting agenda. Regina LaBelle, Chief of Staff from ONDCP and Lisa Robin, Chief Advocacy Officer from the Federation of State Medical Boards, will be joining us for separate brainstorming sessions. Sherry Green, CEO of the National Alliance for Model State Drug Laws, and an expert on the topic of PDMPs, is rearranging her schedule in order to present to us on the challenges facing PDMPs.

I should have the agenda out next week.

Thanks to all.

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance

Mallinckrodt Pharmaceuticals

675 McDonnell Blvd. | Hazelwood, MO 63042 | USA

T: 314.654.3927 | M: 314.308.4961

donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

From: Lohman, Donald A

Sent: Tuesday, November 12, 2013 3:58 PM

To: Giacalone, Robert <Robert.Giacalone@cardinalhealth.com>

(Robert.Giacalone@cardinalhealth.com); Cameron, Todd

(Todd.Cameron@cardinalhealth.com); 'Tom P Napoli'; mclarke@actavis.com;

THernandez@QualitestRX.com; MRichardson@qualitestrx.com; Mays, Steve

(SMays@amerisourcebergen.com); 'EHazewski@amerisourcebergen.com'; Campbell,

Elizabeth (ECampbell@amerisourcebergen.com); Walker, Donald

(Donald.Walker@McKesson.com); krista.peck@mckesson.com;

william.stivers@hdsmith.com

Cc: linden.barber@quarles.com; larry.cote@quarles.com; Harper, Karen; Gillies, John V;

Phillips, Lynn

Subject: Anti-Diversion IWG

All –

To recap the call we had this afternoon:

1. Bob G's Conversation with Carmen Catizone:
 - a. NABP is not in favor of an accreditation program for pharmacies filling a certain volume of opioids.
 - b. Carmen was very supportive of the pharmacist video idea. He said NABP likely would be on board, provided that they had input into the content – which we expected them to have. Carmen will have to get back to the various state boards to see if they would be supportive of doing the intro to the videos, but felt that this would probably be something they would support. In fact, he suggested that if they agreed, we could set up a filming room at the upcoming NABP Annual meeting in May for those "intro" videos to be taken (since the great majority of the state pharmacy board executives attend that function). That would cut down our costs.
 - c. We have solid commitments from Mallinckrodt, Cardinal, ABC and Actavis. **We still need commitments from McKesson, Qualitest and H.D. Smith – please provide by return email. Also, please provide the names of any production companies your company has used that might be appropriate for a 10-15 minute video.** Once we have those names, we will submit an RFP and review responses. Bob, Don and whomever else is interested, will work closely with NABP on developing the content.
2. Next meeting December 10, 2013 in Washington, D.C. The location: offices of Arent Fox at 1717 K Street, NW, Washington, DC 20036. 8 am – 5 pm, as usual. I will have a draft agenda out before Thanksgiving. We hope to cover the following:
 - a. Status of pharmacist video

- b. ONDCP brainstorming. I am sending a follow up email to the Deputy Director this afternoon.
- c. Federation of State Medical Boards brainstorming. I am sending an invitation to Lisa Robin, their Chief Advocacy Officer.
- d. Brainstorming around our meetings with ONDCP and FSMB
- e. Government Affairs Discussion. There is an opportunity to collaborate with Health Counsel, Committee on Energy and Commerce, House of Reps. Perhaps we should bring in our respective Government Affairs people to discuss what makes sense. **If you have not already done so, please send me the contact information for your company's Government Affairs representative and let them know that Craig Burton, with Mallinckrodt, will be in touch on this issue.**
- f. National Alliance for Model State Drug Laws. We will issue an invitation to them concerning PMPs to learn what we can do to make interconnectivity a reality.
- g. Common messaging bullet points for pharmacies on topic of corresponding responsibility.

Linden is reaching out to Joe R's executive assistance to see if DEA is planning on attending. If there are any other topics you would like to cover, please let me know.

Thanks.

Don

Donald A. Lohman | Associate General Counsel
Litigation Management and Controlled Substances Compliance
Mallinckrodt Pharmaceuticals
675 McDonnell Blvd. | Hazelwood, MO 63042 | USA
T: 314.654.3927 | M: 314.308.4961
donald.lohman@mallinckrodt.com | www.mallinckrodt.com

This information may be confidential and/or privileged. Use of this information by anyone other than the intended recipient is prohibited. If you receive this in error, please inform the sender and remove any record of this message.

This message and its attachments are intended for the named addressee only, and may contain confidential, proprietary or legally privileged information. No confidentiality or privilege is waived or lost by any mistransmission. If you have by coincidence or mistake received this email and its attachments, please immediately delete it and all copies of it from your system, destroy any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print or copy any part of this message or its attachments if you are not the intended recipient. Please note that the sender of this e-mail and its attachments is solely responsible for its content if it does not concern the operations of Actavis or its affiliates.